




Q7 02/10/09



PCT

Industria y Comercio

SUPERINTENDENCIA



Organización y Digitalización CSA Ltda

**SOLICITUD
PATENTE DE INVENCION**

09-96401

21. EXPEDIENTE Nº

54. TÍTULO FORMULACIONES PARA APÓSITOS PARA

EVITAR Y REDUCIR LA CICATRIZACIÓN.

51. CLASIFICACIÓN INTERNACIONAL A61F 13/00

71. SOLICITANTE BIOZONE LABORATORIES INC.

DOMICILIO Pittsburg, California, Estados Unidos de América

74. APODERADO DILIA MARIA RODRIGUEZ D'ALEMAN

22. BOGOTÁ, D.C. _____

Podr. Cuz. / Título
En 08-10-2009



No. 09-096401- -00000-0000

Fecha: 2009-09-09 15:08:21 Dep. 2020 NUECREACION
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 48

**FORMULARIO ÚNICO DE SOLICITUD DE PATENTE
PCT
ENTRADA EN FASE NACIONAL**

SOLICITUD DE:

1

☒ Patente de Invención ☐ Patente de Modelo de Utilidad

☒ Capítulo I. ☐ Capítulo II.

**SOLICITANTE
(71)**

Nombre: BIOZONE LABORATORIES INC.
Dirección: 580 Garcia Avenue, Pittsburg,
California 94565, Estados Unidos de América.
Nacionalidad o domicilio: Pittsburg, California,
Estados Unidos de América.
Lugar de Constitución: California, Estados
Unidos de América.
Teléfono: **Fax:**
E-mail

IDENTIFICACIÓN

C.C. ☐ **NIT** ☐

C.E. ☐ **Otro** ☐

Número

**3
REPRESENTANTE
O APODERADO
(74)**

Nombre: DILIA MARÍA RODRÍGUEZ
D'ALEMAN
Dirección: Carrera 11 No. 86-53, piso 6
Teléfono: 6 181088 **Fax:** 6350824
E-mail: clarkemodet@clarkemodet.com.co

IDENTIFICACIÓN

C.C. ☒ **NIT** ☐

C.E. ☐ **Otro** ☐

Número 41.654.882
TP 20824 CSJ

**4
INVENTOR (ES)
(72)**

Nombre: KELLER, Brian, C.
Dirección: 580 Garcia Avenue, Pittsburg, California 94565, Estados Unidos de
América.
Nacionalidad o domicilio: Estadounidense

5 PCT (86)

Solicitud Internacional No. PCT/US2008/056443 **Fecha** 10 de marzo de 2008
Publicación Internacional No. WO 2008/109887 A1 **Fecha** 12 de septiembre de 2008

6 TÍTULO (54) FORMULACIONES PARA APÓSITOS PARA EVITAR Y REDUCIR LA
CICATRIZACIÓN. (Folio 54)

7 Clasificación Internacional (51) A61F 13/00

8 Prioridad

SI ☒ **NO** ☐


(33) País de Origen
Estados Unidos de América

(32) Fecha
8 de marzo de 2007

(31) Número de Solicitud
60/905,984

9 Comprobante de pago No. 09 - 55,082 **Fecha** 27 de julio de 2009

- ☐ Comprobante de pago de la tasa de presentación de la solicitud
- ☐ Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica
- ☐ Poderes si fuere el caso
- ☐ Documento de cesión del inventor al solicitante o a su causante
- ☐ Declaraciones
- ☒ Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos)
- ☒ Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos)
- ☐ Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA).
- ☐ Traducción del examen preliminar internacional efectuado por la IPEA
- ☐ De ser el caso copia de contrato de acceso.
- ☐ De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas
- ☐ De ser el caso, certificado de deposito del material biológico
- ☐ Arte final 12 X 12 .
- ☐ De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- ☐ De ser el caso, modificaciones efectuadas a la solicitud internacional
- ☒ Otros Opinión escrita.

11 FIGURA CARACTERÍSTICA**12 Solicito la concesión de la patente****NOMBRE :** DILIA MARÍA RODRÍGUEZ D'ALEMAN**FIRMA:****C.C. 41.654.882****T.P. 20824**

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 09 - 55,082
FECHA : JULIO 27 DE 2009

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 09-096401- -00000-0000

Fecha: 2009-09-09 15:08:21 Dep. 2020 NUECREACION
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 48

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET Y CO. COLOMB	CONSIGNACION	BANCO DE BOGOTA	062754387	112379363	27/07/2009	95,810,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	540,000.00
		TOTAL :	\$ 540,000.00

SON: QUINIENTOS CUARENTA MIL PESOS

RESPONSABLE :

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

P-7306
2

Resumen de la Descripción

Se proporciona aquí una formulación para apósito para
5 cicatriz que comprende una mezcla de un polímero reticulado
de elastómero de silicona de alto peso molecular y un aceite
de silicona, en donde dicho polímero reticulado de elastómero
de silicona está en un fluido volátil. La formulación tiene
una sensación suave, sedosa sin ser grasosa y rápidamente
10 seca para formar un apósito para cicatriz, flexible, durable.

FORMULACIONES PARA APÓSITOS PARA EVITAR Y REDUCIR LA
CICATRIZACIÓN

Campo Técnico

5

La presente invención se relaciona con apósitos para cicatrización. Más particularmente, la presente invención se relaciona con composiciones para apósitos que evitan o reducen la cicatrización que comprende preparaciones de
10 silicona anhidra aplicadas directamente a la cicatriz.

Técnica Antecedente

La cicatrización resulta de una respuesta de curación
15 fisiológica normal después de incisión o lesión de la piel. El proceso de curación de heridas de la piel consiste de tres fases - inflamación, granulación y remodelamiento de matriz. Durante la primera fase, se monta una respuesta inflamatoria, que produce una cascada de reacciones de químicas que
20 resultan en vasodilatación, exudado que llena la herida, e hinchazón en el sitio de la lesión. La migración neutrófila en el área de la lesión activa la producción de prostaglandinas y libera fosfolipasa A2 (PLA2) que origina daño celular y de tejido. En la segunda fase, tiene lugar la
25 granulación como macrófagos que secretan citoquinas para promover la formación de tejido granulado. Este nuevo tejido consiste de nuevo tejido epitelial completo con nueva vasculatura y suministro de sangre. En la fase tres, ocurre

el remodelamiento de la matriz como proliferación de fibroblastos y fabricación de colágeno, elastina y otros bloques de construcción de tejido en y alrededor del sitio de la herida.

5

Las cicatrices hipertróficas representan una respuesta frecuente pero exagerada a la curación. Clínicamente, las cicatrices hipertróficas se elevan, se ponen rojas y frecuentemente se ponen nodulares. Ello ocurre en todas las áreas de la piel pero es más común en áreas gruesas de la piel. Frecuentemente, las cicatrices hipertróficas se desarrollan dentro de las semanas de una quemadura, cierre de herida, infección de herida, hipoxia y otras lesiones traumáticas de la piel. El colágeno encontrado en este tipo de cicatrices es altamente desorganizado y forma disposiciones similares a espirales a diferencia de la orientación paralela normal, que origina la curación y elevación por encima de la superficie normal de la piel.

20

Las personas con cicatrización de piel anormal enfrentan consecuencias físicas y fisiológicas que se asocian frecuentemente con sustanciales costos financieros y emocionales. Por lo tanto, subsiste una necesidad crítica no cumplida de tratamiento y prevención de la cicatrización. Las opciones de tratamientos actuales varían de ningún tratamiento en los absoluto (es decir, dejar la cicatriz sola); procedimientos invasivos y cirugía tal como corticosteroides intralesionales, terapias láser y

criocirugía, y manejo no invasivo, particularmente a través de medicamentos tópicos, ver, por ejemplo, Zurada et al., J. Am. Acad. Dermatol. 55:1024-31 (2006). La mayor parte de personas que sufren de cicatrices que eligen experimentar tratamiento prefieren utilizar técnicas no invasivas debido a que la conformidad general es mayor, el proceso es autocontrolado y menos doloroso.

Uno de los materiales importantes utilizados en el manejo no invasivo de cicatrices ha sido láminas de gel de polímero polidimetilsiloxona o láminas de gel de silicona. Desde que se introdujeron en 1982, se han utilizado las láminas de gel de siliconas tópicas para minimizar el tamaño, induración, eritema, prurito, y extensibilidad de las cicatrices hipertróficas persistentes con resultados mezclados. Ver, por ejemplo, Fette, Plastic Surg. Nurs. 26:87-92 (2006); de Oliveria et al., Dermatol. Surg. 27:721-26 (2001); Ricketts et al., Dermatol. Surg. 22:955-59 (1996). Sin embargo, los estudios controlados no han demostrado diferencias significativas entre apósitos para heridas con gel y apósitos para heridas basados en silicona. Más aún, la principal desventaja de las láminas de gel de silicona es la dificultad de uso y así, no tienen alta conformidad. Por su naturaleza los geles de silicona son difíciles de manejar. Ellos son suaves y frangibles y las láminas de gel se desgarran con facilidad en uso. Se ha propuesto mejorar la resistencia y facilidad de manejo de las láminas de gel de silicona al incrustar allí durante la fabricación, un

material de soporte tal como una red de poliéster u otras fibras. Aunque esta técnica ha resultado en una mejora en la capacidad de manejo y aplicación de la lámina gel, se ha encontrado que la lámina tiene aún una tendencia a fragmentarse durante la aplicación y uso. Las láminas también se pueden utilizar 24 horas al día durante 2-4 meses.

Buscando evitar algunas de las restricciones con las láminas de gel de silicona, también se han ensayado productos de gel de silicona líquida. Los productos de dimeticona líquida, por ejemplo, tienen la ventaja de facilidad de uso pero de nuevo la conformidad es baja debido a la naturaleza grasosa, desordenada, del líquido dimeticona. Los intentos para reducir o eliminar la naturaleza desordenada de la silicona dependen principalmente de formulaciones complicadas para apósitos de heridas que les faltan la comodidad necesaria y la flexibilidad a largo plazo necesaria para la mayoría de heridas.

Por lo tanto, subsiste la necesidad de apósitos para cicatrización o heridas mejorados que se apliquen fácilmente sin inducir dolor o que comprendan adicionalmente la herida pero que resulten en un apósito flexible y de configuración que suministre suficiente protección para permitir la regeneración de tejido apropiada en el sitio de la lesión.

Descripción de la Invención

La presente invención se relaciona con apósitos para cicatrices que comprenden polímeros reticulados elastómeros de silicona que se aplican fácilmente a heridas cerradas y se curan rápidamente a temperatura ambiente. La mezcla de polímero reticulado de silicona se puede aplicar fácilmente directamente a heridas cerradas y cuando se cura, proporciona un apósito que se aplica fácilmente a heridas recientemente cerradas, es confortable y flexible. Los apósitos suministrados aquí minimizan adicionalmente la cicatrización, reducen potenciales infecciones, y disminuyen la intensidad y duración de la decoloración de la cicatriz.

Más particularmente, se proporciona aquí un apósito para cicatriz que comprende una mezcla de un polímero reticulado elastómero de silicona de alto peso molecular y un aceite de silicona, en donde dicho polímero reticulado elastómero de silicona está en un fluido volátil. El polímero reticulado elastómero de silicona se puede basar en dimeticona o una mezcla de cliclohexasiloxano y ciclopentasiloxano. El aceite de silicona puede ser dimeticona, ciclometicona o una mezcla de los mismos.

El apósito tiene una sensación suave, sedosa sobre la piel luego de la aplicación y se puede aplicar sin producir lesión adicional o inconformidad. Después que se aplica la mezcla a la herida cerrada, la evaporación del diluyente

volátil resulta en una "cura" de la mezcla de silicona para formar un apósito altamente flexible que puede cubrir la herida cerrada o la cicatriz durante periodos largos. Esta puede ser oclusiva. La formulación puede ser un producto de
5 tratamientos de cicatriz que sea fácil de aplicar a las cicatrices recientes, calmante al tejido de la cicatriz, indoloro, libre de efectos colaterales y fácil de utilizar para cumplir con múltiples aplicaciones debido a que no es grasoso, va en seco y ocluye la cicatriz para una mejor
10 oportunidad de curación continuada sin induración, hipertrofia y desfiguración permanente.

Modos de llevar a cabo la Invención

15 A menos que se defina otra cosa, todos los términos técnicos y científicos utilizados aquí tienen el mismo significado como lo entiende una persona medianamente versada en la técnica a la que pertenece esta invención. Todas las patentes, solicitudes, solicitudes publicadas y otras
20 publicaciones referidas aquí se incorporan como referencia en su totalidad. Si una definición establecida en esta sección es contraria a o de otra forma inconsistente con unas definiciones establecidas en las patentes, solicitudes, solicitudes publicadas y otras publicaciones que se
25 incorporan aquí como referencia, la definición establecida en esta sección prevalece sobre la definición que se incorpora aquí como referencia.

Como se utiliza aquí, "un" o "una" significa "por lo menos una" o "una o más".

Las siliconas son un grupo de polímeros completamente
5 sintéticos que contiene el grupo recurrente $--SiR_2O--$, en
donde R es un radical tal como un grupo alquilo, arilo,
fenilo o vinilo. Las siliconas más simples son aceites de muy
bajo punto de fusión, aunque en el otro extremo de la escala
de propiedades físicas son siliconas altamente reticuladas
10 que forman sólidos rígidos. El intermedio en las propiedades
físicas entre estos dos extremos son los elastómeros de
siliconas tal como geles y cauchos. Aunque las siliconas se
forman al reticular una mezcla de dos o más siliconas, pueden
ser diferentes los pesos moleculares de los varios
15 componentes y/o sus grados de sustitución mediante grupos
reactivos. Esto permite a las mezclas tener diferentes
propiedades físicas para ser formadas únicamente al variar
las proporciones de los componentes.

20 Se suministra aquí un apósito para cicatriz (o herida)
que comprende una mezcla de un polímero reticulado de
elastómero de silicona de alto peso molecular y un aceite de
silicona, en donde dicho polímero reticulado de elastómero de
silicona está en un fluido volátil. El polímero reticulado de
25 elastómero de silicona se puede basar en dimeticona o una
mezcla de una mezcla de ciclohexasiloxano y
ciclopentasiloxano. El aceite de silicona puede ser
dimeticona, ciclometicona o una mezcla de los mismos. Los

elastómeros de silicona útiles en los apósitos para herida suministrados son aquellos que se secan rápidamente, tienen una sensación suave, sedosa sobre la piel y agregan una textura lujosa para apósitos cuando se aplica inicialmente.

5 El apósito para cicatriz suministrado aquí puede ser oclusivo y flexible. Los apósitos no son pegajosos ni grasosos.

Se puede emplear cualquier elastómero de silicona de alto peso molecular adecuado. Un elastómero de silicona
10 comprende polímeros de siliconas reticulados. El uso de polímeros de silicona reticulados elimina la necesidad de un catalizador o un agente de reticulación en la formulación en apósito para cicatriz. En algunas modalidades, el peso molecular preferido del elastómero depende de la viscosidad
15 deseada de la formulación de apósito para cicatriz así como también las características deseadas de secado rápido, conformidad, textura, y no pegajosidad. Los elastómeros de ejemplo incluyen polímeros reticulados de dimeticona como en Dow Corning® 9040 (polímero reticulado de elastómero de
20 dimeticona) o KSG-210 (dimeticona/PEG-10/15 polímero reticulado y dimeticona) (ShinEtsu Chemical Co. Ltd) así como también Volasil 7525 (una mezcla de ciclopentasiloxano y ciclohexasiloxano) (Chemisil Silicones Inc.). Típicamente, el polímero reticulado de elastómero de alto peso molecular
25 tiene una baja viscosidad de aproximadamente 50 cSt o menos, aproximadamente 25 cSt o menos, o algunas veces 5 cSt o menos.

El elastómero de silicona está en un fluido volátil. En la mayoría de modalidades, el componente no volátil es menor de aproximadamente 10%, menor de aproximadamente 15%, o menor de aproximadamente 20%, o menos de aproximadamente 30% en peso. Los fluidos volátiles incluyen fluidos de silicona de superbaja viscosidad tal como ciclometicona o dimeticona. El elastómero de silicona en un fluido volátil representa más de aproximadamente 70%, aproximadamente 80%, más de aproximadamente 85%, más de aproximadamente 90%, o más de 95% en peso de la formulación de apósito para herida.

Los aceites de siliconas útiles en la formulación para apósitos para heridas suministrados aquí tienen un contenido alto de no volátiles de más de 70%, más de 80% o más de 90%. Los aceites de silicona de ejemplos incluyen dimeticona, ciclometicona o una mezcla de estos tal como Botanisol S-19 (PEG-12 dimeticona). El aceite de silicona puede estar en una forma de polvo o fluido. En una modalidad, el aceite de silicona puede ser un polímero reticulado de dimeticona/vinilo dimeticona tal como Dow Corning® 9506. La cantidad de aceite de silicona en la formulación de apósito para cicatrización puede estar en forma de aproximadamente 0.5% a aproximadamente 15% por peso. En algunas modalidades, el tamaño de partícula preferido del elastómero depende de la viscosidad deseada de la formulación para apósito para herida así como también las características deseadas de secado rápido, conformidad, textura y no pegajosidad. En general, el rango de tamaño de partícula puede ser de aproximadamente 500

nm a aproximadamente 100 μm . En algunas modalidades, el tamaño de partícula varía de aproximadamente 1 a aproximadamente 15 μm . El tamaño de partícula promedio puede ser de aproximadamente 500nm, aproximadamente 1 μm , 5 aproximadamente 3 μm , aproximadamente 5 μm , aproximadamente 10 μm , aproximadamente 15 μm , o más.

La formulación para apósitos para cicatriz puede contener opcionalmente uno o más aditivos. Los aditivos incluyen, pero no se limitan a agentes terapéuticos, antimicrobianos (que incluyen antibacterianos, antivíricos y antifúngicos), estabilizantes, espesantes, pigmentos, tintes, conservantes y antioxidantes. En una modalidad, la formulación para apósito para cicatriz contiene de aproximadamente 0.001% a aproximadamente 25-35% en peso de por lo menos un aditivo. En una modalidad particular, el aditivo es de aproximadamente 5% o menos por peso, aproximadamente 3% o menos por peso, o aproximadamente 1% por peso o menos.

20

En algunas modalidades, el aditivo puede incrementar la suavidad de la formulación para apósito para cicatriz. Tales aditivos incluyen pero no se limitan a glicerina, propilenglicol, butilenglicol, ésteres, ésteres de diacil glicerol, y almidón.

25

En algunas formulaciones para apósitos para cicatriz, son útiles los conservantes tales como alcohol bencílico. También

se pueden emplear los portadores para agentes terapéuticos y/o antimicrobianos tales como agua.

Específicamente los estabilizantes incluyen
5 estabilizantes amina. Los espesantes adecuados son los
agentes para la hinchazón habitualmente usados para la
formación de gel en una farmacia galénica. Ejemplos de
espesantes adecuados incluyen espesantes orgánicos naturales,
tal como agar--agar, gelatina, goma arábiga, una pectina,
10 etc., compuestos naturales orgánicos modificados, tal como
carboximetilcelulosa o éteres de celulosa, o espesantes
orgánicos completamente sintéticos, tal como compuestos poli
poliacrílicos, polímeros de vinilo, o poliéteres.

15 Agentes terapéuticos incluyen agentes bioactivos pero no
se limitan a antisépticos, agentes antibacterianos, agentes
antifúngicos u otros adyuvantes empleados en el tratamiento
de quemaduras y heridas. Tales agentes incluyen moléculas
orgánicas, orgánicas, preferiblemente compuestos orgánicos
20 pequeños que tienen un peso molecular de mas de 50 y menos de
aproximadamente 2,500 dalton; péptidos, sacáridos, ácidos
grasos, esteroides, purinas, pirimidinas, derivados, y
análogos estructurales. Los agentes terapéuticos también
incluyen agentes de proteínas y péptido, tal como anticuerpos
25 o fragmentos de unión o imitadores de los mismos, por
ejemplo, factores de crecimiento o Fab, Fv, F (ab')₂, que
estimulan la cicatrización y el crecimiento de la piel. Se
suministran aquí los antibióticos y agentes analgésicos tal

como fenilbutazona, oxifenbutazona, indometacina, naproxeno, ibuprofeno, acetaminofen, ácido acetilsalicílico, penicilinas, tetraciclinas, y estreptomycinas que también son adecuados para agentes terapéuticos útiles en la cicatrización.

En una modalidad particular, la formulación para apósitos para cicatriz suministrada aquí incluye liposomas o composiciones liposómicas. Se puede emplear cualquier liposoma o composición liposómica. En algunas modalidades, los liposomas contienen uno o más agentes terapéuticos adecuados para un apósito para herida. Los liposomas de ejemplo incluyen aquellos en la Patente Estadounidense No. 6,958,160 y 7,150,883. En una modalidad, el liposoma comprende uno o más lípidos que es un diacilglicerol-PEG, particularmente dioleoilglicerol-PEG-12.

La Formulación es útil en cualquier etapa durante la evolución de la cicatriz. La formulación se puede aplicar a una herida que ha completado el proceso de re-epitelización inicial o es una herida cerrada. Y la formulación también es útil para tratar cicatrices durante la etapa de contracción, maduración o remodelamiento de curación de herida. Así, la cicatriz puede ser menor de aproximadamente 1 semana de edad, aproximadamente 2 semanas de edad; aproximadamente 1 mes de edad, aproximadamente 3 meses de edad; o más. Las cicatrices que resultan de cualquier tipo de herida se pueden tratar de acuerdo con la presente invención. Tales cicatrices incluyen

pero no se limitan a aquellas que resultan de o se relacionan con cortes, abrasiones, lesión traumática de la piel, quemaduras, y heridas quirúrgicas (tal como aquellas que resultan del uso de un bisturí o un láser). Tales cicatrices

5 pueden ser atróficas, hipertróficas, queloides o contracturas. La formulación para apósitos para heridas suministrada aquí se adapta particularmente para el tratamiento y/o prevención de cicatrices hipertróficas de heridas luego de lesiones de quemaduras.

10

En algunas modalidades, la formulación para apósito para cicatriz se aplica al sitio deseado aunque en un estado sustancialmente fluible. Una vez se mezcla completamente la formulación para apósito para cicatriz, ésta permanece

15 fluible y así aplicable a las superficies de la herida durante hasta 15 minutos. El estado fluible o sustancialmente fluible permite a la formulación para apósito para herida ser ajustada a cualquier superficie o forma de contorno. Así, la formulación se aplica a la cicatriz y se puede trabajar con

20 hasta aproximadamente 2 minutos a aproximadamente 15 minutos para cubrir la cicatriz según sea necesario. Después de la aplicación, la formulación para apósito para cicatriz se suaviza a un espesor deseado y está sustancialmente libre de pegado después de mezcla.

25

La formulación para apósito para herida forma típicamente una membrana que tiene un espesor de aproximadamente 0.1 mm a aproximadamente 5 mm luego de

curado. La membrana puede ser continua o sustancialmente continua sobre la superficie de la cicatriz. La naturaleza continua de la membrana permite al apósito para cicatriz retener la humedad en la cicatriz así como también actuar
5 como una barrera bacteriana. El apósito para cicatriz está libre o por lo menos sustancialmente libre de burbujas de aire.

La formulación para apósito para cicatriz puede ser
10 transparente o sustancialmente transparente. La transparencia permite la observación visual y permite monitorear la cicatriz cuando continua la curación y mejora la apariencia cosmética del apósito (por ejemplo, hacerla menos visible).

15 La formulación para apósito para cicatriz puede permanecer sobre la cicatriz durante cualquier tiempo suficiente para permitir la curación de y/o la resolución de la cicatriz. En una modalidad, la formulación de apósito para cicatriz que forma una membrana permanece en la herida por lo menos
20 aproximadamente un 1, por lo menos aproximadamente 2 días, por lo menos aproximadamente 4 días, por lo menos aproximadamente 6 días, o por lo menos aproximadamente 7 días a aproximadamente 10 días.

25 Después que la formulación para apósito de cicatriz ha estado sobre una cicatriz durante un tiempo suficiente para promover y/o completar sustancialmente la curación y la formación de cicatriz, el apósito para cicatriz se puede

remover al limpiarla gentilmente de la cicatriz. La herida curada se caracteriza por una cicatrización mínima, humedad, y enrojecimientos reducidos.

5 Adicionalmente se suministra aquí un equipo que comprende los componentes de la formulación como se describe aquí y opcionalmente instrucciones para uso.

Se ofrece los siguientes ejemplos para ilustrar pero no
10 limitar la invención.

Ejemplo 1

Formulación para Apósito para Cicatriz que Utiliza Polímeros
15 Reticulados de Dimeticona

El KSG-210 es un polímero reticulado dimeticona y dimeticona/PEG-10/15 que se hincha en fluido de silicona. Las partículas reticuladas diminutas se orientan en la interfaz
20 con el fluido y forman una red. El Botanisil S-19 es un aceite de silicona que es dimeticona PEG-12.

GDM-12 es un tipo específico de liposoma termodinámicamente estable, autoformador, adecuado para el
25 suministro de agentes terapéuticos (Ver, Patente Estadounidense No. 6,958,160). Más específicamente, el GDM-12 es una mezcla de liposomas formado de lípidos dimiristato de glicerol ("GDM") en donde el grupo líder de lípidos incluye

una molécula de polietilenglicol ("PEG") con 12 C₂H₄O en la cadena PEG.

KSG-210	96.7500%	96.7500
Botanisil S-19	0.5000%	0.5000
GDM-12	0.5000%	0.5000
Alcohol Bencílico	0.7500%	0.7500
Agua Purificada	1.5000%	1.5000

Total:	100.0000%	100.0000
--------	-----------	----------

5

Ejemplo #2

Formulación para Apósito para Cicatriz que Utiliza Polímeros Reticulados de Dimeticona

10

Dow Corning® 9040 Silicone Elastomer Blend es una mezcla de un elastómero de silicona de alto peso molecular (es decir, polímero reticulado de dimeticona) en ciclometicona (< 1 % en peso). Este es un diluyente volátil que es un fluido de silicona. Tiene un rango de viscosidad de 250,000-580,000 cp y un contenido de no volátiles típico de 12.0 % en peso a 12.75 % en peso. La Ciclometicona es un aceite de silicona.

20

1	Dow Corning 9040	83.5000%	83.5000
2	Ciclometicona	15.0000%	15.0000
3	Glicerina	1.0000%	1.0000
4	GDM-12	0.5000%	0.5000

	Total:	100.0000%	100.0000
--	--------	-----------	----------

Ejemplo #3

Formulación para Apósito para Cicatriz que Utiliza
5 Polímeros Reticulados Dimeticona

El Volasil 7525 es una mezcla de baja viscosidad de elastómeros ciclohexasiloxano y ciclopentasiloxano. El polvo Dow Corning® 9506 es un aceite de silicona. Más particularmente, Dow Corning® 9506 es un polímero reticulado de dimeticona/vinil dimeticona con un contenido de no volátiles del 98% (mínimo). Es un polvo blanco que fluye libremente que proporciona suavidad en seco y una sensación a la piel no grasosa de polvo liviano. Éste también reduce la
15 pegajosidad.

1	Volasil 7525	85.5000%	85.5000
2	Polvo de Dow Corning® 9506	13.0000%	13.0000
3	Glicerina	1.0000%	1.0000

4	GDM-12	0.5000%	0.5000
	Total:	100.0000%	100.0000

Aunque la invención se ha explicado en relación con sus modalidades preferidas, se entiende que varias modificaciones de esta serán evidentes para aquellos expertos en la técnica luego de la lectura de la especificación. Por lo tanto, se entiende que la invención descrita aquí está destinada a cubrir tales modificaciones que caen dentro del alcance de las reivindicaciones adjuntas.

REIVINDICACIONES

1. Una formulación para apósito para cicatriz que comprende

- 5 a) Un polímero reticulado de silicona de alto peso molecular en un fluido volátil; y
b) Un fluido/aceite de silicona.

10 2. La formulación de la reivindicación 1. En donde el elastómero de silicona de alto peso molecular es un polímero reticulado de dimeticona.

15 3. La formulación de la reivindicación 1, donde dicho elastómero de silicona de alto peso molecular es una mezcla de ciclohexasiloxano y ciclospentasiloxano.

4. La formulación de la reivindicación 1, en donde dicho aceite de silicona es dimeticona, ciclometicona, o una mezcla de los mismos.

20 5. La formulación de la reivindicación 1, que comprende adicionalmente un agente terapéutico.

25 6. La formulación de la reivindicación 4, en donde dicho agente terapéutico se encapsula en un liposoma.

7. Un equipo que comprende los componentes de la formulación de la reivindicación 1.

PCT REQUEST The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.	For receiving Office use only International Application No. International Filing Date Name of receiving Office and "PCT International Application" Applicant's or agent's file reference (if desired) (12 characters maximum) 270142000940
Box No. I TITLE OF INVENTION DRESSING FORMULATIONS TO PREVENT AND REDUCE SCARRING	
Box No. II APPLICANT ☐ This person is also inventor	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) Biozone Laboratories Inc. 580 Garcia Avenue Pittsburg, California 94565 United States of America	Telephone No. (925) 473-1000 Facsimile No. (925) 473-1001 Applicant's registration No. with the Office
State (that is, country) of nationality: US	State (that is, country) of residence: US
This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box	
Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) KELLER, Brian C. 580 Garcia Avenue Pittsburg, California 94565 United States of America	This person is: ☐ applicant only ☒ applicant and inventor ☐ inventor only (If this check-box is marked, do not fill in below.) Applicant's registration No. with the Office
State (that is, country) of nationality: US	State (that is, country) of residence: US
This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box	
☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.	
Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE	
The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) MURASHIGE, Kate H. Morrison & Foerster LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040 United States of America	Telephone No. (858) 720-5112 Facsimile No. (858) 720-5125 Agent's registration No. with the Office 29,959
☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.	

Supplemental Box	If the Supplemental Box is not used, this sheet should not be included in the request.
1. If, in any of the Boxes, except Boxes Nos. VIII(i) to (v) for which a special continuation box is provided, the space is insufficient to furnish all the information: in such case, write "Continuation of box No." (indicate the number of the Box) and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular: (i) if more than two persons are to be indicated as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below; (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant; (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor; (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box IV; (v) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI. 2. If the applicant intends to make an indication of the wish that the international application be treated, in certain designated States, as an application for a patent of addition, certificate of addition, inventor's certificate of addition or utility certificate of addition: in such a case, write the name or two-letter code of each designated State concerned and the indication "patent of addition," "certificate of addition," "inventor's certificate of addition" or "utility certificate of addition," the number of the parent application or parent patent or other parent grant and the date of grant of the parent patent or other patent grant or the date of filing of the parent application (Rules 4.11(a)(iii) and 49bis.1(a) or (b)). 3. If the applicant intends to make an indication of the wish that the international application be treated, in the United States of America, as a continuation or continuation-in-part of an earlier application: in such a case, write "United States of America" or "US" and the indication "continuation" or "continuation-in-part" and the number and the filing date of the parent application (Rules 4.11(a)(iv) and 49bis.1(d)).	Continuation of Box No. IV: Lisa A. Amii, 48,199; Mehran Arjomand, 48,231; Shantanu Basu, 43,318; Vincent J. Belusko, 30,820; Jonathan Bockman, 45,640; Kimberly A. Bolin, 44,546; Barry E. Bretschneider, 28,055; Robert K. Cerpa, 39,933; Thomas Chan, 51,543; Alex Chartove, 31,942; Peng Chen, 43,543; S. Laura Chung, 59,875; Thomas E. Ciotti, 21,013; Peter J. Davis, 36,119; Brian Donahue, 58,206; Christopher B. Eide, 48,375; Gregory P. Einhorn, 38,440; Ernest Ellenberger, 56,529; Eric J. Fechter, 60,588; David L. Fehrman, 28,600; Brian N. Fletcher, 51,683; Hector G. Gallegos, 40,614; Deborah S. Gladstein, 43,636; Debra J. Glaister, 33,888; Alicia J. Hager, 44,140; Brigitte A. Hajos, 50,971; Vicki L. Healy, 48,343; Kelly E. Hershey, 48,408; Brian B. Ho, 60,199; David Hoffman, 59,821; Charles D. Holland, 35,196; Parisa Jorjani, 46,813; Adam Keser, 54,217; Richard C. Kim, 40,046; Norman R. Klivans, 33,003; Jeffie Kopczynski, 56,395; Glenn M. Kubota, 44,197; Kaare D. Larson, 51,920; Katherine D. Lee, 44,865; Paul J. Lee, 52,420; Yan Leychikis, 60,440; Catherine O. Liang, 61,778; Adam C. Lilling, 60,272; Otis Littlefield, 48,751; Milka Mayer, 47,777; Robert S. McArthur, 45,674; Bradley J. Meier, 44,236; Elizabeth Cary Miller, 54,708; Gladys H. Monroy, 32,430; Scott C. Moore, 52,047; James J. Mullen, III, 44,957; Kate H. Murashige, 29,959; Martin Noonan, 44,264; Diane Pardi, 56,824; Margaret Pierri, 30,709; Catherine M. Polizzi, 40,130; Rory J. Radding, 28,759; Shannon Reaney, 52,285; Leslie A. Robinson, 54,403; Ryan G. Roemer, 55,872; Robert A. Saltzberg, 36,910; Terri Shieh-Newton, 47,081; Rebecca Shortle, 47,083; Michael G. Smith, 44,422; Cassandra T. Swain, 48,361; Eric Tisdale, 60,110; Elahe Toosi, 57,740; Thomas L. Treffert, 48,279; Patricia Tsao, 50,713; Hristo I. Vachovsky, 55,694; Daniel E. Valencia, 56,463; John M. Vassiliades, 57,382; Brenda J. Wallach, 45,193; Cecilia A. Walsh, 45,659; Michael R. Ward, 38,651; Todd W. Wight, 45,218; Denise H. Wong, 59,622; Mitchell M. Wong, 48,034; Frank Wu, 41,386; Walter Wu, 50,816; Janet Xiao, 55,748; David T. Yang, 44,415; Alex Yap, 60,609; Peter J. Yim, 44,417; Stephanie Yonker, 58,528; Timothy J. Young, 58,705; and Jie Zhou, 52,395

Box No. V DESIGNATIONS

The filing of this request constitutes under Rule 4.9(a), the designation of all Contracting States bound by the PCT on the international filing date, for the grant of every kind of protection available and, where applicable, for the grant of both regional and national patents.

However,

- ☐ DE Germany is not designated for any kind of national protection.
- ☐ JP Japan is not designated for any kind of national protection.
- ☐ KR Republic of Korea is not designated for any kind of national protection.
- ☐ RU Russian Federation is not designated for any kind of national protection.

(The check-boxes above may be used to exclude (irrevocably) the designations concerned if, at the time of filing or subsequently under Rule 26bis.1, the international application contains in Box No. VI a priority claim to an earlier national application filed in the particular State concerned, in order to avoid the ceasing of the effect, under the national law, of this earlier national application.)

Box No. VI PRIORITY CLAIM

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country or Member of WTO	regional application: regional Office	international application receiving Office
item (1) 08 March 2007 (08.03.2007)	60/905,984	US		
item (2)				
item (3)				

☐ Further priority claims are indicated in the Supplemental Box.

Transmit certified copy: the receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☒ all items ☐ item (1) ☐ item (2) ☐ item (3) ☐ other, see Supplemental Box

Restore the right of priority: the receiving Office is requested to restore the right of priority for the earlier application(s) identified above or in the Supplemental Box as item(s) (). (See also the Notes to Box No. VI; further information must be provided to support a request to restore the right of priority.)

Incorporation by reference: where an element of the international application referred to in Article 11(1)(iii)(d) or (e) or a part of the description, claims or drawings referred to in Rule 20.5(a) is not otherwise contained in this international application but is completely contained in an earlier application whose priority is claimed on the date on which one or more elements referred to in Article 11(1)(iii) were first received by the receiving Office, that element or part is, subject to confirmation under Rule 20.6, incorporated by reference in this international application for the purposes of Rule 20.6.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code maybe used):

ISA /US

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year) Number Country (or regional Office)

Box No. VIII DECLARATIONS

The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):

		Number of declarations
☐ Box No. VIII (i)	Declaration as to the identity of the inventor	:
☐ Box No. VIII (ii)	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	:
☐ Box No. VIII (iii)	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	:
☐ Box No. VIII (iv)	Declaration of inventorship (only for the purposes of the designation of the United States of America)	:
☐ Box No. VIII (v)	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	:

Box No. IX CHECK LIST; LANGUAGE OF FILING			
This international application contains: (a) on paper, the following number of sheets: request (including declaration and supplemental sheets) : 4 description (excluding sequence listings and/or tables related thereto) : 8 claims : 1 abstract : 1 drawings : _____ Sub-total number of sheets : 14 sequence listings : _____ tables related thereto : _____ <i>(for both, actual number of sheets if filed on paper, whether or not also filed in electronic form; see (c) below)</i> Total number of sheets : 14 (b) ☐ only in electronic form (Section 801(a)(i)) (i) ☐ sequence listings (ii) ☐ tables related thereto (c) ☐ also in electronic form (Section 801(a)(ii)) (i) ☐ sequence listings (ii) ☐ tables related thereto Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the ☐ sequence listing: ☐ tables related thereto: <i>(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)</i>	This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item): 1. ☒ fee calculation sheet : 1 2. ☐ original separate power of attorney : 3. ☐ original general power of attorney : 4. ☐ copy of general power of attorney; reference number, if any: : 5. ☐ statement explaining lack of signature : 6. ☐ priority document(s) identified in Box No. VI as item(s): : 7. ☐ translation of international application into (language): : 8. ☐ separate indications concerning deposited microorganisms or other biological material : 9. ☐ sequence listing in electronic form (indicate type and number of carriers) : (i) ☐ copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application) : (ii) ☐ (only where check-box (b)(i) or (c)(i) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter : (iii) ☐ together with relevant statement as to the identity of the copy or copies with the sequence listing part mentioned in left column : 10. ☐ tables in electronic form related to sequence listing (indicate type and number of carriers) : (i) ☐ copy submitted for the purposes of international search under Section 802 (b-quater) only (and not as part of the international application) : (ii) ☐ (only where check-box (b)(ii) or (c)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Section 802 (b-quater) : (iii) ☐ together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column : 11. ☒ other (specify): Transmittal : 1		Number of items
Figure of the drawings which should accompany the abstract:	Language of filing of the international application: English		
Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE <i>Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).</i> _____ /Kate H. Murashige, Reg. No. 29,959/ Kate H. Murashige, Agent for Applicant(s) MORRISON & FOERSTER LLP			
1. Date of actual receipt of the purported international application: _____ 3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application: _____ 4. Date of timely receipt of the required corrections under PCT Article 11(2): _____		For receiving Office use only Drawings: ☐ received: ☐ not received:	
5. International Searching Authority (if two or more are competent): ISA /	6. ☐ Transmittal of search copy delayed until search fee is paid.		
For International Bureau use only Date of receipt of the record copy by the International Bureau: _____			

This sheet is not part of and does not count as a sheet of the international application.

PCT		For receiving Office use only	
FEE CALCULATION SHEET		International Application No. _____	
Annex to the Request		Date stamp of the receiving Office _____	
Applicant's or agent's file reference 270142000940	Applicant Biozone Laboratories Inc.		
CALCULATION OF PRESCRIBED FEES			
1. TRANSMITTAL FEE	300.00	T	
2. SEARCH FEE	1,800.00	S	
International search to be carried out by <u>US</u> (If two or more International Searching Authorities are competent to carry out the international search, indicate the name of the Authority which is chosen to carry out the international search.)			
3. INTERNATIONAL FILING FEE			
Where item (b) and/or (c) of Box No. IX apply, enter Sub-total number of sheets } <u>14</u> Where item (b) and (c) of Box No. IX do not apply, enter Total number of sheets			
☐ i1 first 30 sheets	1,109.00	☐ i1	
☐ i2 _____ x 13.00 = _____		☐ i2	
number of sheets in excess of 30 fee per sheet			
☐ i3 additional component (only if sequence listing and /or tables related thereto are filed in electronic form under Section 801(a)(i), or both in that form and on paper, under Section 801(a)(ii):			
400 x _____ = _____			
fee per sheet			
Add amounts entered at i1, i2 and i3 and enter total at I			
1,109.00 ☐ I			
(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the international filing fee.)			
4. FEE FOR PRIORITY DOCUMENT (if applicable)			
_____ ☐ P			
5. TOTAL FEES PAYABLE			
\$3,209.00			
TOTAL			
Add amounts entered at T, S, I and P, and enter total in the TOTAL box			
MODE OF PAYMENT (Not all modes of payment may be available at all receiving Offices)			
☒ authorization to charge deposit account (see below) ☐ postal money order ☐ cash ☐ coupons			
☐ cheque ☐ bank draft ☐ revenue stamps ☐ other (specify): _____			
AUTHORIZATION TO CHARGE (OR CREDIT) DEPOSIT ACCOUNT (This mode of payment may not be available at all receiving Offices)			
☒ Authorization to charge the total fees indicated above.			
☒ This check-box may be marked only if the conditions for deposit accounts of the receiving office so permit) Authorization to charge any deficiency or credit any overpayment in the total fees indicated above.			
☒ Authorization to charge the fee for priority document.			
Receiving Office: RO/ <u>US</u>			
Deposit Account No.: <u>03-1952</u>			
Date: <u>10 March 2008</u>			
Name: <u>Kate H. Murashige</u>			
Signature: <u>/Kate H. Murashige, Reg.</u>			
No. <u>29,959/</u>			

PATENT COOPERATION TREATY

RECEIVED

APR 04 2008

From the RECEIVING OFFICE

PCT

MORRISON & FOERSTER
SAN DIEGO DOCKETING

To:

KATE H. MURASHIGE
MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE, SUITE 100
SAN DIEGO, CALIFORNIA 92130-2040

AXS

NOTIFICATION CONCERNING PAYMENT
OF PRESCRIBED FEES(PCT Rules 14, 15 and 16 and Administrative
Instructions, Sections 102bis(c), 304,
323(b), 707(b) and 803)Date of mailing
(day/month/year)

03 Apr 2008

Applicant's or agent's file reference

270142000940

PAYMENT DUE

see item 3 for time limits

International application No.

PCT/US2008/056443

International filing date/Date of receipt
(day/month/year)

10 Mar 2008

Priority date (day/month/year)

08 Mar 2007

Applicant

BIOZONE LABORATORIES INC.

1. The applicant is hereby notified that this receiving Office has received:

- ☒ the payment of all the prescribed fees, and ☐ an overpayment, which will be refunded in due course.
☐ no or insufficient payment of the prescribed fees and the applicant is hereby invited to pay the balance due, as summarized under item 2, within the time limit(s) indicated under item 3.

2. Fees and payment calculation:

3,209.00	-	3,209.00	=	0.00
Total fees payable		Amount paid		Balance

- ☐ The details of the calculation are given in the Annex.

3. Time limit(s) for payment and amount(s) payable (Rules 14.1, 15.4 and 16.1(f)):

- ☐ within ONE MONTH from the date of receipt of the international application (for the transmittal fee (if any), the search fee and the international filing fee). The amount payable for each fee is the amount applicable on the date of receipt of the international application.
- ☐ within 16 MONTHS from the priority date (only for the fee for priority document). The applicant's attention is drawn to the fact that the request made by the applicant under Rule 17.1(b) will be considered not to have been made unless the fee is paid within that time limit.

4. Additional observations (if necessary):

- ☐ The search copy will not be transmitted to the International Searching Authority until the search fee is paid (therefore the start of the international search will be delayed) (Rule 23.1(a) and (b)).

Name and mailing address of the receiving Office

Mail Stop PCT, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450
Facsimile No. 571-273-3201

Authorized officer

Eric Simms

Telephone No. 703-308-9290 EX 120

Form PCT/RO/102 (January 2004)

No Docketing Required

Reviewed by Docketing

Initials

MR

ANNEX TO FORM PCT/RO/102
CALCULATION OF THE PRESCRIBED FEES

International application No.
PCT/US2008/056443

T Transmittal Fee

Prescribed amount: 300.00 **T**
Amount paid: - 300.00
Balance: = 0.00

☒ correct amount
☐ overpayment
☐ balance due

S Search Fee

Prescribed amount: 1,800.00 **S**
Amount paid: - 1,800.00
Balance: = 0.00

☒ correct amount
☐ overpayment
☐ balance due

I International Filing Fee

Fixed amount for first 30 sheets: 1,109.00 **i1**
0 x 13.00 = 0.00 **i2**
Number of sheets Fee per sheet
in excess of 30
Additional
component: . . . 400 x 0.00 = 0.00 **i3**
Fee per sheet

Reduction where the international application is filed
(See PCT Applicant's Guide, Volume I, General Part,
for details on the availability of this reduction):

using the PCT-EASY software: - 0.00 **r**

or

in electronic form where the text of the
description, claims and abstract is not in
character coded format: - 0.00 **r**

or

in electronic form where the text of the
description, claims and abstract is in character
coded format: - 0.00 **r**

Sub-total: = 1,109.00 **i1+i2+i3-r**

Prescribed total amount (The amount to be entered at I is the sub-total
entered at i1+i2+i3-r, except where the applicant is (or all applicants
are) entitled to a reduction of 75%, in which case the amount to be
entered at I is 25% of the sub-total (i1+i2+i3-r); certain applicants from
certain States are entitled to a reduction of 75% of the international
filing fee; see Notes to the Fee Calculation Sheet as annexed to the
Request Form, PCT/RO/101, for details): =

1,109.00 **I**
Amount paid: - 1,109.00
Balance: = 0.00

☒ correct amount
☐ overpayment
☐ balance due

P Fee for Priority Document

Prescribed amount: 0.00 **P**
Amount paid: - 0.00
Balance: = 0.00

☒ correct amount
☐ overpayment
☐ balance due

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number
WO 2008/109887 A1

(51) International Patent Classification:
A61F 13/00 (2006.01) A61F 15/00 (2006.01)

(21) International Application Number:
PCT/US2008/056443

(22) International Filing Date: 10 March 2008 (10.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/905,984 8 March 2007 (08.03.2007) US

(71) Applicant (for all designated States except US): BIO-
ZONE LABORATORIES INC. [US/US]; 580 Garcia
Avenue, Pittsburg, CA 94565 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KELLER, Brian, C.
[US/US]; 580 Garcia Avenue, Pittsburg, CA 94565 (US).

(74) Agent: MURASHIGE, Kate H.; Morrison & Foerster
LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA
92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every
kind of regional protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC,
LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: DRESSING FORMULATIONS TO PREVENT AND REDUCE SCARRING

(57) Abstract: Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible scar dressing.

WO 2008/109887 A1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 08/56443

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61F 13/00, A61F 15/00 (2008.04) USPC - 602/52 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC8 : A61F 13/00, A61F 15/00 (2008.04) USPC : 602/52 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched IPC8 : A61L 15/00, A61L 26/00 (2008.04) USPC : 602/42, 602/41, 602/51, 602/48 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PubWEST (PGPB,USPT,EPAB,JPAB), Google Scholar dimethicone, PDMS, polydimethylsiloxane, cyclohexasiloxane, cyclopentasiloxane, dodecamethyl, silicone, liquid, fluid, oil, volatile, solvent, crosspolymer, crosslinked, high molecular weight, siloxane, scarring, scar, dressing, bandage		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages.	Relevant to claim No.
X	US 4,987,893 A (SALMONE et al) 29 January 1991 (29.01.1991) see especially col 2, ln 31-36, col 2, ln 66 to col 3, ln 3, col 3, ln 7 to col 4, ln 62, col 9, ln 40-49, col 9, ln 63-68	1, 4, 5, 7
Y		2, 3, 6
Y	US 2003/0180281 A1 (BOTT et al) 25 September 2003 (25.09.2003) see especially para [0036]-[0042]	2, 3
Y	US 6,958,160 B1 (KELLER et al) 25 October 2005 (25.10.2005) see especially col 7, ln 47-53	6
☐ Further documents are listed in the continuation of Box C. ☐		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 6 June 2008 (06.06.2008)		Date of mailing of the international search report 23 JUN 2008
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201		Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

TRANSMITTAL LETTER TO THE UNITED STATES RECEIVING OFFICE

Express Mail mailing number:	Date of deposit: 10 MARCH 2008
File reference no.: 270142000940	International application no. (if known): Not Yet Assigned
Title of the invention: DRESSING FORMULATIONS TO PREVENT AND REDUCE SCARRING	
Earliest priority date claimed (Day/Month/Year): 08 March 2007 (08.03.2007)	

☒ This is a new International Application

SCREENING DISCLOSURE INFORMATION

In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (check as many boxes as apply):

- ☐ The invention disclosed was **not** made in the United States of America.
- ☐ There is no prior U.S. application relating to this invention.
- ☒ The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: priority to these applications may or may not be claimed on the Request (form PCT/RO/101) and this listing does not constitute a claim for priority.)

application no.	60/905,984	filed on	08 March 2007 (08.03.2007)
application no.		filed on	
application no.		filed on	
application no.		filed on	
application no.		filed on	

- ☐ The present international application contains additional subject matter not found in the prior U.S. application(s) identified above. The additional subject matter is found on pages _____ and ☐ DOES NOT ALTER ☐ MIGHT BE CONSIDERED TO ALTER the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37 C.F.R. 5.15.

Itemized list of contents

Sheets of Request form: 4	Check no.:
Sheets of description (excluding sequence listing): 8	Return receipt postcard:
Sheets of claims: 1	Power of attorney:
Sheets of abstract: 1	Certified copy of priority document (specify):
Sheets of drawings:	Other (specify): PCT Fee Calculation Sheet (1 sheet)
Sheets of sequence listing:	
Sequence listing diskette/CD:	
Tables related to sequence listing CD:	

The person signing this form is:

- ☐ Applicant
- ☒ Attorney/Agent (Reg. No.)
29,959
- ☐ Common Representative

Kate H. Murashige

Name of person signing

Signature: /Kate H. Murashige, Reg. No. 29,959/

PATENT COOPERATION TREATY

RECEIVED

APR 04 2008

From the RECEIVING OFFICE

PCT

MORRISON & FOERSTER
SAN DIEGO DOCKETING

To:

KATE H. MURASHIGE
MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE, SUITE 100
SAN DIEGO, CALIFORNIA 92130-2040

AXS

NOTIFICATION OF THE INTERNATIONAL
APPLICATION NUMBER AND OF THE
INTERNATIONAL FILING DATE

(PCT Rule 20.2(c))

Confirmation No: 9669

Date of mailing
(day/month/year)

03 Apr 2008

Applicant's or agent's file reference

270142000940

IMPORTANT NOTIFICATION

International application No.

PCT/US2008/056443

International filing date (day/month/year)

10 Mar 2008

Priority date (day/month/year)

08 Mar 2007

Applicant

BIOZONE LABORATORIES INC.

Title of the invention

DRESSING FORMULATIONS TO PREVENT AND REDUCE SCARRING

1. The applicant is hereby notified that the international application has been accorded the international application number and the international filing date indicated above.

2. The applicant is further notified that the record copy of the international application:

03 Apr 2008



was transmitted to the International Bureau on



has not yet been transmitted to the International Bureau for the reason indicated below and a copy of this notification has been sent to the International Bureau*:



because the necessary national security clearance has not yet been obtained.



because (reason to be specified):

* The International Bureau monitors the transmittal of the record copy by the receiving Office and will notify the applicant (with Form PCT/IB/301) of its receipt. Should the record copy not have been received by the expiration of 14 months from the priority date, the International Bureau will notify the applicant (Rule 22.1(c)).

3. FOREIGN TRANSMITTAL LICENSE INFORMATION

Completed by: ES



Additional license for foreign transmittal not required. This subject matter is covered by a license already granted or the equivalent U.S. national application. Refer to that license for information concerning its scope.



License for foreign transmittal not required. 37 CFR 5.11(e)(1) or 37 CFR 5.11(e)(2). However, a license may be required for additional subject matter. See 37 CFR 5.15(b).



Foreign transmittal license granted. 35 U.S.C. 184; 37 CFR 5.11 on 28 Mar 2008

(date)



37 CFR 5.15(a)



37 CFR 5.15(b)

Name and mailing address of the receiving Office

Mail Stop PCT, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450
Facsimile No. 571-273-3201

Authorized officer

Eric Simms

Telephone No. 703-308-9290 EX 120

Form PCT/RO/105 (April 2007)

"No Docketing Required"

Reviewed by Docketing

Initials

MP

33
4

PATENT COOPERATION TREATY

RECEIVED

APR 04 2008

MORRISON & FOERSTER
SAN DIEGO DOCKETING

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF RECEIPT
OF SEARCH COPY

(PCT Rule 25.1)

To: KATE H. MURASHIGE MORRISON & FOERSTER LLP 12531 HIGH BLUFF DRIVE, SUITE 100 SAN DIEGO, CALIFORNIA 92130-2040 AXS		Date of mailing (day/month/year) 03 Apr 2008	
PALM Tracking Number = 51856443		IMPORTANT NOTIFICATION	
Applicant's or agent's file reference 270142000940		Priority date (day/month/year) 08 Mar 2007	
International application No. PCT/US2008/056443	International filing date (day/month/year) 10 Mar 2008	Priority date (day/month/year) 08 Mar 2007	
Applicant BIOZONE LABORATORIES INC.			

- Where the International Searching Authority and the receiving Office are not the same Office:**
 The applicant is hereby notified that the search copy of the international application was received by this International Searching Authority on the date indicated below.

Where the International Searching Authority and the receiving Office are the same Office:
 The applicant is hereby notified that the search copy of the international application was received on the date indicated below.

03 Apr 2008 (date of receipt)
- ☐ The search copy was accompanied by a nucleotide and/or amino acid sequence listing or tables related thereto in computer readable form.
- Time limit for establishment of international search report and written opinion of the International Searching Authority**
 The applicant is informed that the time limit for establishing the international search report and the written opinion of the International Searching Authority is three months from the date of receipt indicated above or nine months from the priority date, whichever time limit expires later (Rules 42.1 and 43bis.1(a)).
- A copy of this notification has been sent to the International Bureau and, where the first sentence of paragraph 1 applies, to the receiving Office.

Name and mailing address of the ISA/
 Mail Stop PCT, Commissioner for Patents
 P.O. Box 1450, Alexandria, VA 22313-1450
 Facsimile No. 571-273-3201

Authorized officer
 Eric Simms
 Telephone No. 703-308-9290 EX 120

Form PCT/ISA/202 (January 2004)

"No Docketing Required" Reviewed by Docketing Initials <u>MR</u>

34
48

RECEIVED

JUN 26 2008

MORRISON & FOERSTER
SAN DIEGO DOCKETING

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To: KATE H. MURASHIGE
MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE, SUITE 100
SAN DIEGO, CA 92130-2040
JUNE 11, 2008 11/2/08
REMINDER: 1/8/09
FINAL DEADLINE: 1/8/09

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT AND
THE WRITTEN OPINION OF THE INTERNATIONAL
SEARCHING AUTHORITY, OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing (day/month/year)	23 JUN 2008
Applicant's or agent's file reference 270142000940	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US 08/56443	International filing date (day/month/year) 10 March 2008 (10.03.2008)
Applicant BIOZONE LABORATORIES INC.	

1. ☒ The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes
1211 Geneva 20, Switzerland, Facsimile No.: +41 22 740 14 35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	--

Form PCT/ISA/220 (January 2004)

(See notes on accompanying sheet)

JUNE 11, 2008 7/23/08
REMINDER: 8/23/08
FINAL DEADLINE: 8/23/08

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

RECEIVED

JUN 26 2008

MORRISON & FOERSTER
SAN DIEGO DOCKETING

Applicant's or agent's file reference 270142000940	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/US 08/56443	International filing date (day/month/year) 10 March 2008 (10.03.2008)	(Earliest) Priority Date (day/month/year) 08 March 2007 (08.03.2007)
Applicant BIOZONE LABORATORIES INC.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of:

- ☒ the international application in the language in which it was filed.
☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

b. ☐ This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).

c. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, see Box No. I.

2. ☐ Certain claims were found unsearchable (see Box No. II).

3. ☐ Unity of invention is lacking (see Box No. III).

4. With regard to the title,

- ☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

- ☒ the text is approved as submitted by the applicant.
☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the drawings,

- a. the figure of the drawings to be published with the abstract is Figure No. _____
☐ as suggested by the applicant.
☐ as selected by this Authority, because the applicant failed to suggest a figure.
☐ as selected by this Authority, because this figure better characterizes the invention.
- b. ☐ none of the figures is to be published with the abstract.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 08/56443

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61F 13/00, A61F 15/00 (2008.04)

USPC - 602/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC8 : A61F 13/00, A61F 15/00 (2008.04)

USPC : 602/52

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

IPC8 : A61L 15/00, A61L 26/00 (2008.04)

USPC : 602/42, 602/41, 602/51, 602/48

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST (PGPB,USPT,EPAB,JPAB), Google Scholar

dimethicone, PDMS, polydimethylsiloxane, cyclohexasiloxane, cyclopentasiloxane, dodecamethyl, silicone, liquid, fluid, oil, volatile, solvent, crosspolymer, crosslinked, high molecular weight, siloxane, scarring, scar, dressing, bandage

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,987,893 A (SALMONE et al) 29 January 1991 (29.01.1991) see especially col 2, ln 31-36, col 2, ln 66 to col 3, ln 3, col 3, ln 7 to col 4, ln 62, col 9, ln 40-49, col 9, ln 63-68	1, 4, 5, 7
Y		2, 3, 6
Y	US 2003/0180281 A1 (BOTT et al) 25 September 2003 (25.09.2003) see especially para [0036]-[0042]	2, 3
Y	US 6,958,160 B1 (KELLER et al) 25 October 2005 (25.10.2005) see especially col 7, ln 47-53	6

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

6 June 2008 (06.06.2008)

Date of mailing of the international search report

23 JUN 2008

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

PATENT COOPERATION TREATY

RECEIVED

JUN 26 2008

From the
INTERNATIONAL SEARCHING AUTHORITY

PCT

MORRISON & FOERSTER
SAN DIEGO DOCKETING

To:
KATE H. MURASHIGE
MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE, SUITE 100
SAN DIEGO, CA 92130-2040

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing
(day/month/year)

23 JUN 2008

Applicant's or agent's file reference
270142000940

FOR FURTHER ACTION

See paragraph 2 below

International application No.
PCT/US 08/56443

International filing date (day/month/year)
10 March 2008 (10.03.2008)

Priority date (day/month/year)
08 March 2007 (08.03.2007)

International Patent Classification (IPC) or both national classification and IPC
IPC(8) - A61F 13/00, A61F 15/00 (2008.04)
USPC - 602/52

Applicant BIOZONE LABORATORIES INC.

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☒ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Date of completion of this opinion
6 June 2008 (06.06.2008)

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US 08/56443

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of:
 - ☒ the international application in the language in which it was filed.
 - ☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. ☐ This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this opinion has been established on the basis of:
 - a. type of material
 - ☐ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☐ on paper
 - ☐ in electronic form
 - c. time of filing/furnishing
 - ☐ contained in the international application as filed
 - ☐ filed together with the international application in electronic form
 - ☐ furnished subsequently to this Authority for the purposes of search
4. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US 08/56443

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1. Statement				
Novelty (N)	Claims	2, 3, 6		YES
	Claims	1, 4, 5, 7		NO
Inventive step (IS)	Claims	None		YES
	Claims	1-7		NO
Industrial applicability (IA)	Claims	1-7		YES
	Claims	None		NO
2. Citations and explanations:				
Claims 1, 4, 5 and 7 lack novelty under PCT Article 33(2) as being anticipated by US 4,987,893 A to Salamone et al (hereinafter Salamone). Regarding claim 1, Salamone discloses a scar dressing formulation (col 9, ln 40-49) comprising: a) a high molecular weight silicone crosspolymer in a volatile fluid (col 2, ln 31-36 and col 3 ln 7 to col 4, ln 34); and b) a silicone fluid/oil (col 4, ln 43-45). Regarding claim 4, Salamone further discloses that said silicone oil is dimethicone, cyclomethicone, or a mixture thereof (col 4, ln 43-45, dimethicone is a polydimethylsiloxane). Regarding claim 5, Salamone further discloses a therapeutic agent (col 2, ln 66 to col 3, ln 3). Regarding claim 7, Salamone discloses a kit comprising the components of the formulation of claim 1 (col 9, ln 63-68, aerosol dispenser). Claims 2 and 3 lack an inventive step under PCT Article 33(3) as being obvious over Salamone in light of US 2003/0180281 A1 to Bott et al (hereinafter Bott). Regarding claim 2, Salamone does not specifically teach that said high molecular weight silicone elastomer is a dimethicone crosspolymer. Salamone teaches a wide variety of polymers (col 3 ln 7 to col 4, ln 34). Bott teaches a similar composition which notably uses polydimethylsiloxane (para [0036]-[0038], [0042]). While Bott does not specifically teach this formulation as a scar dressing, it would have been obvious to one skilled in the art that Salamone could be modified by the teaching of Bott to provide a dressing as claimed because such materials are widely used and have known biocompatibility. Regarding claim 3, Salamone does not specifically teach that said high molecular weight silicone elastomer is a blend of cyclohexasiloxane and cyclopentasiloxane. Salamone teaches a wide variety of polymers including cyclopentasiloxane (col 3 ln 7 to col 4, ln 62). Bott teaches a similar composition which also uses a wide variety of siloxanes (para [0036]-[0042]). There are a large number of different siloxanes and siloxane blends on the market all with specific properties such as viscosity etc. It would have been obvious to one skilled in the art that Salamone and Bott could be modified as claimed through routine experimentation in order to provide a substance that is easy to handle and spreads easily onto the wound. Claim 6 lacks an inventive step under PCT Article 33(3) as being obvious over Salamone in light of US 6,958,160 B1 to Keller et al (hereinafter Keller). Regarding claim 6, Salamone does not specifically teach that said therapeutic agent is encapsulated in a liposome. Salamone teaches incorporating therapeutic agents (col 2, ln 66 to col 3, ln 3). Keller teaches the use of liposome encapsulated therapeutic agents (col 7, ln 47-53). It would have been obvious to one skilled in the art that Salamone could be modified by Keller as claimed in order to prevent the therapeutics interacting with the polymer. Claims 1-7 have industrial applicability as defined by PCT Article 33(4) because the subject matter can be made or used in industry.				

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US 08/56443

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 6 is appended to claim 4, however there is no antecedent for the "said therapeutic agent" in claim 4. This is considered to be a typographical error, for the purposes of this opinion claim 6 has been assumed to be dependant on claim 5.

Claims 2 and 3 refer to the "said high molecular weight silicone elastomer", strictly there is no antecedent for "elastomer" in claim 1. However, silicones are known elastomers and it does not affect the scope of the claims and has been ignored.

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the *PCT Applicant's Guide*, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report and the written opinion of the International Searching Authority, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only (see *PCT Applicant's Guide*, Volume I/A, Annexes B1 and B2).

The attention of the applicant is drawn to the fact that amendments to the claims under Article 19 are not allowed where the International Searching Authority has declared, under Article 17(2), that no international search report would be established (see *PCT Applicant's Guide*, Volume I/A, paragraph 296).

What parts of the international application may be amended ?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When ? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments ?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How ? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments ?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

RECEIVED

PATENT COOPERATION TREATY

PCT/US2008/056443

MAY 14 2008

MORRISON & FOERSTER
SAN DIEGO DOCKETING

From the INTERNATIONAL BUREAU

PCT Initials

* No Docketing Required *
Reviewing by Docketing
CTS

NOTIFICATION OF RECEIPT OF
RECORD COPY

(PCT Rule 24.2(a))

MURASHIGE, Kate H. **AXS**
Morrison & Foerster LLP
12531 High Bluff Drive, Suite 100
San Diego, CA 92130-2040
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)

25 April 2008 (25.04.2008)

IMPORTANT NOTIFICATION

Applicant's or agent's file reference

270142000940

International application No.

PCT/US2008/056443

The applicant is hereby notified that the International Bureau has received the record copy of the international application as detailed below.

Name(s) of the applicant(s) and State(s) for which they are applicants:

BIOZONE LABORATORIES INC. (for all designated States except US)
KELLER, Brian, C. (for US)

International filing date:

10 March 2008 (10.03.2008)

Priority date(s) claimed:

08 March 2007 (08.03.2007)

Date of receipt of the record copy by the International Bureau:

30 March 2008 (30.03.2008)

List of designated Offices:

AP: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

EA: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR

OA: BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

National: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

ATTENTION: The applicant should carefully check the data appearing in this notification. In case of any discrepancy between these data and the indications in the international application, the applicant should immediately inform the International Bureau. **In addition, the applicant's attention is drawn to the information contained in the Annex, relating to:**

- time limits for entry into the national phase - see updated important information (as of April 2002)
- requirements regarding priority documents (if applicable)

A copy of this notification is being sent to the receiving Office and to the International Searching Authority.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Borton Claudio

e-mail pt04.pct@wipo.int

Telephone No. +41 22 338 74 04

Facsimile No. +41 22 338 89 95

INFORMATION ON ENTERING THE NATIONAL PHASE

The applicant is reminded that the **"national phase" must be entered** before each of the designated Offices indicated on the cover sheet of this notification by paying national fees and furnishing translations, as prescribed by Articles 22 and 39 and the applicable national laws. In addition, the applicant may also have to comply with **other special requirements** applicable in certain Offices. It is the **applicant's responsibility** to ensure that the necessary steps to enter the national phase are taken in a timely fashion. Most Offices do not issue reminders to applicants in connection with the entry into the national phase.

The **applicable time limit** for entering the national phase will, **subject to what is said in the following paragraph**, be **30 MONTHS** from the priority date, not only in respect of any elected Office if a demand for international preliminary examination is filed before the expiration of 19 months from the priority date (see Article 39(1)), but also in respect of any designated Office, in the absence of filing of such demand, where Article 22(1) as modified with effect from 1 April 2002 applies in respect of that designated Office. For further details, see *PCT Gazette* No. 44/2001 of 1 November 2001, pages 19926, 19932 and 19934, as well as the *PCT Newsletter*, October and November 2001 and February 2002 issues.

In practice, **time limits other than the 30-month time limit will continue to apply, for various periods of time**, in respect of certain designated or elected Offices. For **regular updates on the applicable time limits (20, 21, 30 or 31 months, or other time limit)**, Office by Office, refer to the *PCT Gazette* ("Section IV" part published on a weekly basis), to the *PCT Newsletter* (on a monthly basis) and to the relevant National Chapters in Volume II of the *PCT Applicant's Guide* (the paper version of which is updated usually twice a year and the Internet version of which is updated usually on a weekly basis). Finally, a cumulative table of all applicable time limits for entering the national phase is available from WIPO's Internet site, via links from various pages of the site, including those of the *Gazette*, *Newsletter* and *Guide*, at <http://www.wipo.int/pct/en/index.html>.

Information about the requirements for **filing a demand for international preliminary examination** is set out in the *PCT Applicant's Guide*, Volume I/A, Chapter IX. Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination (at present, all PCT Contracting States are bound by Chapter II).

REQUIREMENTS REGARDING PRIORITY DOCUMENTS

For applicants who have not yet complied with the requirements regarding priority documents, the following is recalled.

Where the priority of an earlier national, regional or international application is claimed, the applicant must submit a copy of the said earlier application, certified by the authority with which it was filed ("the priority document") to the receiving Office (which will transmit it to the International Bureau) or directly to the International Bureau, before the expiration of 16 months from the priority date, provided that any such priority document may still be submitted to the International Bureau before the date of international publication of the international application, in which case that document will be considered to have been received by the International Bureau on the last day of the 16-month time limit (Rule 17.1(a)).

Where the priority document is issued by the receiving Office, the applicant may, instead of submitting the priority document, request the receiving Office to prepare and transmit the priority document to the International Bureau. Such request must be made before the expiration of the 16-month time limit and may be subjected by the receiving Office to the payment of a fee (Rule 17.1(b)).

If the priority document concerned is not submitted to the International Bureau and if the request to the receiving Office to prepare and transmit the priority document has not been made (and the corresponding fee, if any, paid) within the applicable time limit indicated under the preceding paragraphs, any designated State may disregard the priority claim, provided that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances (Rule 17.1(c)).

Where several priorities are claimed, the priority date to be considered for the purposes of computing the 16-month time limit (and all other PCT time limits) is the filing date of the earliest application whose priority is claimed (Article 2(xi)(b)).

RECEIVED

MAY 14 2008

MORRISON & FOERSTER
SAN DIEGO DOCKETING

* No Docketing
PCT COOPERATION TREATY

Reviewing by Docketing

Initials

CTS

PCT/US2008/056443

PCT

NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

From the INTERNATIONAL BUREAU

To:

MURASHIGE, Kate H. **AXS**
Morrison & Foerster LLP
12531 High Bluff Drive, Suite 100
San Diego, CA 92130-2040
ETATS-UNIS D'AMERIQUE

(PCT Administrative Instructions, Section 411)

Date of mailing (day/month/year) 28 April 2008 (28.04.2008)	
Applicant's or agent's file reference 270142000940	IMPORTANT NOTIFICATION
International application No. PCT/US2008/056443	International filing date (day/month/year) 10 March 2008 (10.03.2008)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 08 March 2007 (08.03.2007)
Applicant BIOZONE LABORATORIES INC. et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable) An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
08 March 2007 (08.03.2007)	60/905,984	US	30 March 2008 (30.03.2008)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Athina Nickitas-Etienne

e-mail PT04.PCT@WIPO.INT

Telephone No. +41 22 338 74 04

Facsimile No. +41 22 338 82 70

45
28

PATENT COOPERATION TREATY

WO 2008/109887
PCT/US2008/056443

From the INTERNATIONAL BUREAU

PCT

FIRST NOTICE INFORMING THE APPLICANT OF
THE COMMUNICATION OF THE INTERNATIONAL
APPLICATION (TO DESIGNATED OFFICES WHICH
DO NOT APPLY THE 30 MONTH TIME LIMIT
UNDER ARTICLE 22(1))

(PCT Rule 47.1(c))

To:

AXS
MURASHIGE, Kate H.
Morrison & Foerster LLP
12531 High Bluff Drive, Suite 100
San Diego, CA 92130-2040
ETATS-UNIS D'AMERIQUE

RECEIVED

OCT 29 2008

MORRISON & FOERSTER
SAN DIEGO DOCKETING

Date of mailing (day/month/year)
09 October 2008 (09.10.2008)

Applicant's or agent's file reference
270142000940

IMPORTANT NOTICE

International application No.
PCT/US2008/056443

International filing date (day/month/year)
10 March 2008 (10.03.2008)

Priority date (day/month/year)
08 March 2007 (08.03.2007)

Applicant

BIOZONE LABORATORIES INC. et al

- ATTENTION:** For any designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002 (30 months from the priority date), **does apply**, please see Form PCT/IB/308(Second and Supplementary Notice) (to be issued promptly after the expiration of 28 months from the priority date).
- Notice is hereby given that the following designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002, **does not apply**, has/have requested that the communication of the international application, as provided for in Article 20, be effected under Rule 93bis.1. The International Bureau has effected that communication on the date indicated below:
12 September 2008 (12.09.2008)

None

In accordance with Rule 47.1(c-bis)(i), those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

- The following designated Offices, for which the time limit under Article 22(1), as in force from 1 April 2002, **does not apply**, have not requested, as at the time of mailing of the present notice, that the communication of the international application be effected under Rule 93bis.1:

LU, TZ, UG

In accordance with Rule 47.1(c-bis)(ii), those Offices accept the present notice as conclusive evidence that the Contracting State for which that Office acts as a designated Office does not require the furnishing, under Article 22, by the applicant of a copy of the international application.

- TIME LIMITS for entry into the national phase**

For the designated Office(s) listed above, and unless a demand for international preliminary examination has been filed before the expiration of **19 months** from the priority date (see Article 39(1)), the applicable time limit for entering the national phase will, **subject to what is said in the following paragraph**, be **20 MONTHS** from the priority date.

In practice, **time limits other than the 20-month time limit** will continue to apply, for various periods of time, in respect of certain of the designated Offices listed above. For **regular updates on the applicable time limits** (20 or 21 months, or other time limit), Office by Office, refer to the *PCT Gazette*, the *PCT Newsletter* and the *PCT Applicant's Guide*, Volume II, National Chapters, all available from WIPO's Internet site, at <http://www.wipo.int/pct/en/index.html>.

It is the applicant's **sole responsibility** to monitor all these time limits.

No Docketing Required

Reviewed by Docketing

Initials

MR

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Athina Nickitas-Etienne

Facsimile No. +41 22 338 82 70

e-mail: pt04.pct@wipo.int

PATENT COOPERATION TREATY

WO 2008/109887
PCT/US2008/056443

From the INTERNATIONAL BUREAU

PCT

SECOND AND SUPPLEMENTARY NOTICE
INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION (TO DESIGNATED OFFICES
WHICH APPLY THE 30 MONTH TIME
LIMIT UNDER ARTICLE 22(1))

(PCT Rule 47.1(c))

To:

LEJ
MURASHIGE, Kate H.
Morrison & Foerster LLP
12531 High Bluff Drive, Suite 100
San Diego, CA 92130-2040
ETATS-UNIS D'AMERIQUE

RECEIVED

JUL 22 2009

MORRISON & FOERSTER
SAN DIEGO DOCKETING

Date of mailing (day/month/year)
09 July 2009 (09.07.2009)

Applicant's or agent's file reference
270142000940

IMPORTANT NOTICE

International application No.
PCT/US2008/056443

International filing date (day/month/year)
10 March 2008 (10.03.2008)

Priority date (day/month/year)
08 March 2007 (08.03.2007)

Applicant

BIOZONE LABORATORIES INC. et al

- ATTENTION:** For any designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002 (30 months from the priority date), **does not apply**, please see Form PCT/IB/308(First Notice) issued previously.
- Notice is hereby given that the following designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002, **does apply**, has/have requested that the communication of the international application, as provided for in Article 20, be effected under Rule 93bis.1. The International Bureau has effected that communication on the date indicated below:
12 September 2008 (12.09.2008)

AU, AZ, BY, CN, CO, DZ, EP, HU, KG, KP, KR, MD, MK, MY, MZ, NA, NG, PG, RU, SY, TM, US

In accordance with Rule 47.1(c-bis)(i), those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

- The following designated Offices, for which the time limit under Article 22(1), as in force from 1 April 2002, **does apply**, have not requested, as at the time of mailing of the present notice, that the communication of the international application be effected under Rule 93bis.1:

AE, AG, AL, AM, AO, AP, AT, BA, BB, BG, BH, BR, BW, BZ, CA, CH, CR, CU, CZ, DE, DK, DM, DO, EA, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KM, KN, KZ, LA, LC, LK, LR, LS, LT, LY, MA, ME, MG, MN, MW, MX, NI, NO, NZ, OA, OM, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TN, TR, TT, UA, UZ, VC, VN, ZA, ZM, ZW

In accordance with Rule 47.1(c-bis)(ii), those Offices accept the present notice as conclusive evidence that the Contracting State for which that Office acts as a designated Office does not require the furnishing, under Article 22, by the applicant of a copy of the international application.

4. TIME LIMITS for entry into the national phase

For the designated or elected Office(s) listed above, the applicable time limit for entering the national phase will, **subject to what is said in the following paragraph**, be 30 MONTHS from the priority date.

In practice, **time limits other than the 30-month time limit** will continue to apply, for various periods of time, in respect of certain of the designated or elected Office(s) listed above. For **regular updates on the applicable time limits** (30 or 31 months, or other time limit), Office by Office, refer to the *PCT Gazette*, the *PCT Newsletter* and the *PCT Applicant's Guide*, Volume II, National Chapters, all available from WIPO's Internet site, at <http://www.wipo.int/pct/en/index.html>.

It is the applicant's **sole responsibility** to monitor all these time limits.

No Docketing Required

Reviewed by Docketing

Initials

mm

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Athina Nickitas-Etienne


Facsimile No. +41 22 338 82 70

e-mail: pt04.pct@wipo.int

PATENT COOPERATION TREATY

WO 2008/109887
PCT/US2008/056443

From the INTERNATIONAL BUREAU



PCT

NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION

To:

RECEIVED

AXS

MURASHIGE, Kate H.
Morrison & Foerster LLP
12531 High Bluff Drive, Suite 100
San Diego, CA 92130-2040
ETATS-UNIS D'AMERIQUE

OCT 01 2008

**MORRISON & FOERSTER
SAN DIEGO DOCKETING**

Date of mailing (day/month/year)
12 September 2008 (12.09.2008)

Applicant's or agent's file reference
270142000940

IMPORTANT NOTICE

International application No.
PCT/US2008/056443

International filing date (day/month/year)
10 March 2008 (10.03.2008)

Priority date (day/month/year)
08 March 2007 (08.03.2007)

Applicant

BIOZONE LABORATORIES INC. et al

The applicant is hereby **notified** that the International Bureau:

☒ has **published** the above-indicated international application on 12 September 2008 (12.09.2008) under
No. WO 2008/109887

☐ has **republished** the above-indicated international application on under
No. WO

For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the published international application.

A copy of the international application is available for viewing and downloading on WIPO's web site at the following address:
www.wipo.int/pctdb (under "Query" enter the PCT or WO number).

The applicant may also obtain a paper copy of the published international application from the International Bureau in writing from
patentscope@wipo.int or the contact details provided below.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Athina Nickitas-Etienne

Facsimile No. +41 22 338 82 70

e-mail: pt04.pct@wipo.int

48
56

**REQUISITOS MÍNIMOS PARA ADMISIÓN A TRAMITE
PCT**

PATENTE DE INVENCION

☒

MODELO DE UTILIDAD ☐

- ◆ Indicación de que se solicita la concesión de una patente ☒
- ◆ Datos de identificación del solicitante o de la persona que presenta la solicitud ☒
- ◆ Descripción de la invención ☒
- ◆ Dibujos de ser estos pertinentes ☐
- ◆ Comprobante de pago de las tasas establecidas ☒

COMPLETA ☐

INCOMPLETA ☐

DISEÑO INDUSTRIAL ☐

- ◆ Indicación de que se solicita el registro de Diseño Industrial ☐
- ◆ Datos de identificación del solicitante o de la persona que presenta la solicitud ☐
- ◆ Representación gráfica y fotográfica del Diseño Industrial o muestra del material que incorpora el diseño ☐
- ◆ Comprobante de pago de las tasas establecidas ☐

COMPLETA ☐

INCOMPLETA ☐

ESQUEMA DE TRAZADO ☐

- ◆ Indicación de que se solicita el registro de un Esquema de Trazado ☐
- ◆ Datos de identificación del solicitante o de la persona que presenta la solicitud ☐
- ◆ Representación gráfica del esquema trazado ☐
- ◆ Comprobante de pago de las tasas establecidas ☐

COMPLETA ☐

INCOMPLETA ☐


Firma Responsable

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Fecha_



No. 09-096401- -00000-0000

Fecha: 2009-09-09 15:08:21 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 48

arrera 13 No. 27-00 Piso 5,7y10'

Conmutador: 3 82 0840

Fax: 3505220

E-mail: info@sic.gov.co

www.sic.gov.co

Bogotá D.C. - Colombia

REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Bogotá,
2020

Doctor(a)
RODRIGUEZ D^a ALEMAN DILIA MARIA

REFERENCIA	Radicación No.	9 96401
	Solicitud internacional	PCT/US2008/056443
	Fecha inicio fase nacional	08/10/2009
	Trámite	11
	Evento	378
	Actuación	430
	Oficio No.	11950

Como resultado del examen de forma, realizado con fundamento en el artículo 38 de la Decisión 486 de la Comisión de la Comunidad Andina, artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la Superintendencia de Industria y Comercio, se le comunica que:

1. La solicitud no contiene el poder debidamente otorgado, con el lleno de los requisitos exigidos por los artículos 63 y subsiguientes del Código de Procedimiento Civil. Adicionalmente, deberá presentar el documento que acredita la existencia y representación legal de la sociedad solicitante, cuando ésta fuere persona jurídica.

2. El solicitante debe presentar un nuevo título que permita identificar la materia de la cual trata la solicitud, ya que el título relacionado no se encuentra con la precisión necesaria para identificar claramente el objeto de la solicitud de patente. (Regla 4.3 PCT, Art 26-27 D-486, Circular Única 5.2.9)

3. La solicitud no contiene la copia del documento en que consta la cesión del derecho a la patente del inventor al solicitante o a su causante, conforme a lo establecido por el artículo 26 literal k) de la Decisión 486 de la Comisión de la Comunidad Andina. Cuando se trate de documentos otorgados en el extranjero, estos deberán legalizarse de conformidad con lo dispuesto por los artículos 259 y 260 del Código de Procedimiento Civil. Cuando se trate de las declaraciones a que hace referencia la Regla 4.17 ii) del Tratado de Cooperación en Materia de Patentes PCT., el alcance de las tales declaraciones se determinará según indiquen claramente una cesión de derechos del inventor al solicitante o su causante, de conformidad con lo dispuesto en el numeral 5.2.15 del Capítulo Quinto, Título X de la Circular Única de Superintendencia de Industria y Comercio.

En cumplimiento de lo dispuesto por el artículo 39 de la Decisión 486, se le requiere para que dentro del término de dos meses siguientes a la fecha de notificación del presente oficio, complete los requisitos anteriormente enunciados. En caso de no dar cumplimiento al presente requerimiento, la solicitud se considerará abandonada y perderá su prelación.


Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal

Continúa en la página siguiente...

REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Radicación No.: 9 96401

e), del capítulo quinto del título primero de la Circular Unica No.10 de 2001.


ALIX CARMENZA CESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

El anterior requerimiento fue notificado por fijación en lista de
fecha 23 OCT. 2009
adpall